Remikiren
From Wikipedia, the free encyclopedia
 |
|
|
Remikiren
|
|
| Systematic (IUPAC) name | |
| (2R)-2-(tert-butylsulfonylmethyl)-N-[(2S)-1- {[(2R,3S,4R)-1-cyclohexyl-4-cyclopropyl-3,4- dihydroxybutan-2-yl]amino}-3-(3H-imidazol- 4-yl)-1-oxopropan-2-yl]-3-phenylpropanamide |
|
| Identifiers | |
| CAS number | |
| ATC code | C09 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C33H50N4O6S |
| Mol. mass | 630.839 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 83% |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Remikiren is a renin inhibitor under development for the treatment of hypertension (high blood pressure). It was first developed by Hoffmann–La Roche in 1996.[1]
[edit] References
- ^ Richter WF, Whitby BR, Chou RC (1996). "Distribution of remikiren, a potent orally active inhibitor of human renin, in laboratory animals". Xenobiotica 26 (3): 243–54. PMID 8730917.
 |
This antihypertensive-related article is a stub. You can help Wikipedia by expanding it. |
|
|||||||||||
